Search
Research
Genome-wide association study identifies peanut allergy-specific loci and evidence of epigenetic mediation in US childrenFood allergy (FA) affects 2%-10% of US children and is a growing clinical and public health problem.
Research
Early introduction of food reduces food allergy – Pro and ConWhen an infant is developmentally ready, a variety of nutritious foods should be introduced including the ‘more allergenic’ foods during infancy
Research
Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infantsThe purpose of this article is to highlight emerging evidence for existing allergy prevention guidelines regarding potential benefits of supporting early...
Research
Gene-vitamin D interactions on food sensitization: A prospective birth cohort studyIt has been hypothesized that vitamin D deficiency (VDD) contributes to the development of food sensitization (FS) and then food allergy.
Research
Epigenome-wide association study reveals longitudinally stable DNA methylation differences in CD4+ T cells from children with IgE-mediated food allergyFood allergy is mediated by a combination of genetic and environmental risk factors, potentially mediated by epigenetic mechanisms.
Research
EAACI food allergy and anaphylaxis guidelines: diagnosis and management of food allergyFood allergy can have significant effects on morbidity and quality of life and can be costly in terms of medical visits and treatments.
News & Events
Cow’s milk protein allergies on the rise in our kidsUp to three out of every 100 babies develop cow's milk protein allergy (CMPA) in their first year of life – and this number appears to be on the rise
News & Events
ORIGINS reaches key milestoneORIGINS, a collaboration between The Kids and the Joondalup Health Campus, has achieved a major milestone – recruiting its 1000th family.
News & Events
The Kids Research Institute Australia researchers share in TPCHRF fundingEight The Kids Research Institute Australia researchers are among those who have received grant funding from the Telethon-Perth Children’s Hospital Research Fund (TPCHRF).
Research
Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPEThe pivotal phase 3 EPITOPE trial, a 12-month, double-blind, placebo-controlled study of epicutaneous immunotherapy with the VIASKIN patch containing 250 μg of peanut protein (VP250), previously reported significant treatment response versus placebo in peanut-allergic toddlers aged 1 through 3 years.